Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Neuroligin-1 is altered in Alzheimer’s disease

Jonathan Brouillette • 6 May 2020
Alzheimer’s Disease

Jonathan Brouillette, PhD, University of Montreal, Montreal, Quebec, Canada, outlines a study investigating whether neuroligin-1 (NLGN1) is altered in the hippocampus of Alzheimer’s disease (AD) patients as well as whether it modulates cognitive functions during Aβo-driven neurodegeneration. This interview was recorded during an online conference call with The Video Journal of Dementia (VJDementia).

More from Jonathan Brouillette

2:41
NLGN1: potential biomarker of Alzheimer’s disease
Jonathan Brouillette • 6 May 2020

Related Videos

3:58
Promising FONLISA test for ultrasensitive detection of plasma NfL in Alzheimer’s disease
Madison Honey • 7 Mar 2024
4:12
Updates in Alzheimer’s treatment: the potential of NSC001
Manfred Windisch • 6 Mar 2024
4:44
Influence of genetic risk for psychiatric disorders on dementia
Jenna Najar • 6 Mar 2024
2:06
The role of governments in addressing the access issues to dementia treatment
Paola Barbarino • 23 Mar 2024
The content of VJDementia is intended for healthcare professionals